7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sakiyama H et al. | Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. | 2001 | J. Bone Miner. Metab. | pmid:11448014 |
| Choi Y et al. | Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. | 2001 | Eur. J. Immunol. | pmid:11449372 |
| Kanzaki H et al. | Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. | 2001 | J. Dent. Res. | pmid:11379890 |
| Hein GE | [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. | 2001 | Z Rheumatol | pmid:11383046 |
| Morony S et al. | Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. | 2001 | Cancer Res. | pmid:11389072 |
| Kim KJ et al. | Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. | 2001 | J. Biomed. Mater. Res. | pmid:11410897 |
| Abu-Amer Y | IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. | 2001 | J. Clin. Invest. | pmid:11390419 |
| Kon T et al. | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | 2001 | J. Bone Miner. Res. | pmid:11393777 |
| Fazzalari NL et al. | The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. | 2001 | J. Bone Miner. Res. | pmid:11393778 |
| Bekker PJ et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | 2001 | J. Bone Miner. Res. | pmid:11204435 |
| Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Stejskal D et al. | Osteoprotegerin, RANK, RANKL. | 2001 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:12426773 |
| Stejskal D et al. | Osteoprotegerin and bone density. | 2001 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:12426776 |
| Takemura M et al. | Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. | 2001 | Metab. Clin. Exp. | pmid:11172466 |
| Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
| Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
| Browner WS et al. | Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11158021 |
| Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
| Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
| Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
| Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
| Kuntz KA et al. | An immunohistochemical study of osteoprotegerin in the human dental pulp. | 2001 | J Endod | pmid:11716077 |
| Hofbauer LC and Schoppet M | Serum measurement of osteoprotegerin--clinical relevance and potential applications. | 2001 | Eur. J. Endocrinol. | pmid:11720890 |
| Ueland T et al. | Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. | 2001 | Eur. J. Endocrinol. | pmid:11720891 |
| Chikazu D et al. | Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. | 2001 | J. Bone Miner. Res. | pmid:11697804 |
| Khosla S | Minireview: the OPG/RANKL/RANK system. | 2001 | Endocrinology | pmid:11713196 |
| Seidel C et al. | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. | 2001 | Blood | pmid:11568016 |
| Fukagawa M et al. | Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. | 2001 | Am. J. Kidney Dis. | pmid:11576943 |
| Sato T et al. | Osteoprotegerin levels before and after renal transplantation. | 2001 | Am. J. Kidney Dis. | pmid:11576949 |
| Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
| Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
| Quinn JM et al. | Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | 2001 | J. Bone Miner. Res. | pmid:11585342 |
| Choi SJ et al. | Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. | 2001 | J. Bone Miner. Res. | pmid:11585344 |
| Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
| Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hofbauer LC and Schoppet M | Osteoprotegerin: a link between osteoporosis and arterial calcification? | 2001 | Lancet | pmid:11498208 |
| Sakai A et al. | 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. | 2001 | J. Bone Miner. Metab. | pmid:11498729 |
| Ikeda T et al. | Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. | 2001 | J. Bone Miner. Res. | pmid:11499864 |
| Thomas GP et al. | Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. | 2001 | J. Endocrinol. | pmid:11479141 |
| Allan GF et al. | Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. | 2001 | Steroids | pmid:11546554 |
| Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
| Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
| Ramalho AC et al. | Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. | 2001 | Cytokine | pmid:11792122 |
| Yano K et al. | Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. | 2001 | J. Bone Miner. Metab. | pmid:11685652 |
| Kawahara N et al. | Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. | 2001 | Chem. Pharm. Bull. | pmid:11605678 |
| Boissy P et al. | RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11606048 |
| Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
| Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Yan T et al. | Regulation of osteoclastogenesis and RANK expression by TGF-beta1. | 2001 Aug 1-9 | J. Cell. Biochem. | pmid:11573248 |
| Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
| Sakata M et al. | Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. | 2002 | Cytokine | pmid:12126649 |
| Petersson M et al. | Oxytocin stimulates proliferation of human osteoblast-like cells. | 2002 | Peptides | pmid:12126740 |
| Cundy T et al. | A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. | 2002 | Hum. Mol. Genet. | pmid:12189164 |
| Williamson E et al. | Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. | 2002 | J. Immunol. | pmid:12244151 |
| Lee SK et al. | 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. | 2002 | J. Immunol. | pmid:12193704 |
| Chen XW et al. | Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12150965 |
| Katagiri T and Takahashi N | Regulatory mechanisms of osteoblast and osteoclast differentiation. | 2002 | Oral Dis | pmid:12108759 |
| Li X et al. | Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. | 2002 | Bone | pmid:11934647 |
| Jiang Y et al. | Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. | 2002 | Infect. Immun. | pmid:12011008 |
| Granchi D et al. | Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. | 2002 | Biomaterials | pmid:12013183 |
| Li X et al. | Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. | 2002 | Prostaglandins Other Lipid Mediat. | pmid:12013525 |
| Bosshart H | Expression of survival receptors in Hodgkin disease cell lines. | 2002 | Blood | pmid:12001908 |
| Ono K et al. | Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. | 2002 | J. Bone Miner. Res. | pmid:12009007 |
| Palenzuela L et al. | Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. | 2002 | J. Med. Genet. | pmid:12362049 |
| Fu Q et al. | Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. | 2002 | J. Biol. Chem. | pmid:12364326 |
| Rogers A et al. | Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12364420 |
| Romas E et al. | Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. | 2002 | Am. J. Pathol. | pmid:12368214 |
| Standal T et al. | Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. | 2002 | Blood | pmid:12351414 |
| Sandor M et al. | A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. | 2002 | Biomaterials | pmid:12219832 |
| Shiotani A et al. | Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. | 2002 | Anat. Rec. | pmid:12221720 |
| Cremer I et al. | Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. | 2002 | Blood | pmid:12393586 |
| Giuliani N et al. | Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. | 2002 | Blood | pmid:12393684 |
| Liao EY et al. | Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. | 2002 | J. Endocrinol. Invest. | pmid:12398237 |
| Kazama JJ et al. | Circulating osteoprotegerin is not removed through haemodialysis membrane. | 2002 | Nephrol. Dial. Transplant. | pmid:12271009 |
| Roux S et al. | RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. | 2002 | Br. J. Haematol. | pmid:11918537 |
| Lee SW et al. | TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. | 2002 | J. Biochem. Mol. Biol. | pmid:12296995 |
| Oshiro T et al. | Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. | 2002 | Anat. Rec. | pmid:11920384 |
| Redlich K et al. | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. | 2002 | Arthritis Rheum. | pmid:11920416 |
| Bengtsson AK and Ryan EJ | Immune function of the decoy receptor osteoprotegerin. | 2002 | Crit. Rev. Immunol. | pmid:12498383 |